Immunotherapeutic strategies for treating opioid use disorder and overdose

被引:7
作者
Luba, Rachel [1 ,3 ]
Martinez, Suky [1 ]
Jones, Jermaine [1 ]
Pravetoni, Marco [2 ]
Comer, Sandra D. [1 ]
机构
[1] Columbia Univ, New York State Psychiat Inst, Irving Med Ctr, Div Subst Use Disorders, New York, NY USA
[2] Univ Washington, Ctr Med Dev Subst Use Disorders & Overdose, Sch Med, Dept Psychiat & Behav Sci,Dept Pharmacol, Seattle, WA USA
[3] Columbia Univ, New York State Psychiat Inst, Irving Med Ctr, Div Subst Use Disorders, 1051 Riverside Dr Rm 3737, New York, NY 10032 USA
关键词
Vaccines; immunotherapies; opioid use disorder; substance use disorders; heroin; oxycodone; fentanyl; opioids; nicotine; Cocaine; NICOTINE CONJUGATE VACCINE; COCAINE VACCINE; MONOCLONAL-ANTIBODY; ACTIVE IMMUNIZATION; THERAPEUTIC VACCINE; EFFICACY; IMMUNOGENICITY; HEROIN; MORPHINE; HAPTEN;
D O I
10.1080/13543784.2023.2173062
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionDevelopment and implementation of effective treatments for opioid use disorder (OUD) and prevention of overdose are urgent public health needs. Though existing medications for OUD (MOUD) are effective, barriers to initiation and retention in treatment persist. Therefore, development of novel treatments, especially those may complement existing treatments, is needed.Areas coveredThis review provides an overview of vaccines for substance use disorders (SUD) and mechanisms underlying their function and efficacy. Next, we focus on existing preclinical and clinical trials of SUD vaccines. We focus briefly on related strategies before providing an expert opinion on prior, current, and future work on vaccines for OUD. We included published findings from preclinical and clinical trials found on PubMed and ScienceDirect as well as ongoing or initiated trials listed on ClinicalTrials.gov.Expert opinionThe present opioid overdose and OUD crises necessitate urgent development and implementation of effective treatments, especially those that offer protection from overdose and can serve as adjuvants to existing medications. Promising preclinical trial results paired with careful efforts to develop vaccines that account for prior SUD vaccine shortcomings offer hope for current and future clinical trials of opioid vaccines. Clinical advantages of opioid vaccines appear to outnumber disadvantages, which may result in improved treatment options.
引用
收藏
页码:77 / 87
页数:11
相关论文
共 125 条
  • [1] Akbarzadeh A, 1999, BIOTECHNOL APPL BIOC, V30, P139
  • [2] Akbarzadeh A., 2009, Journal of Pharmacology and Toxicology, V4, P30, DOI 10.3923/jpt.2009.30.35
  • [3] [Anonymous], 2002, CPDD ANN M
  • [4] Drug Overdose Deaths Before and After Shelter-in-Place Orders During the COVID-19 Pandemic in San Francisco
    Appa, Ayesha
    Rodda, Luke N.
    Cawley, Caroline
    Zevin, Barry
    Coffin, Phillip O.
    Gandhi, Monica
    Imbert, Elizabeth
    [J]. JAMA NETWORK OPEN, 2021, 4 (05)
  • [5] Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review
    Armenian, Patil
    Vo, Kathy T.
    Barr-Walker, Jill
    Lynch, Kara L.
    [J]. NEUROPHARMACOLOGY, 2018, 134 : 121 - 132
  • [6] Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl,Alfentanil, Sufentanil, and Acetylfentanyl in Rats
    Baehr, Carly
    Robinson, Christine
    Kassick, Andrew
    Jahan, Rajwana
    Gradinati, Valeria
    Averick, Saadyah E.
    Runyon, Scott P.
    Pravetoni, Marco
    [J]. ACS OMEGA, 2022, 7 (19): : 16584 - 16592
  • [7] Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats
    Baehr, Carly
    Kelcher, April Huseby
    Khaimraj, Aaron
    Reed, Dana E.
    Pandit, Sujata G.
    AuCoin, David
    Averick, Saadyah
    Pravetoni, Marco
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2020, 375 (03) : 469 - 477
  • [8] Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity
    Baehr, Carly A.
    Wu, Mariah M.
    Pandit, Sujata G.
    Arias-Umana, Jose
    AuCoin, David
    Pravetoni, Marco
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 381 (02) : 129 - 136
  • [9] Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins
    Baruffaldi, Federico
    Kelcher, April Huseby
    Laudenbach, Megan
    Gradinati, Valeria
    Limkar, Ajinkya
    Roslawski, Michaela
    Birnbaum, Angela
    Lees, Andrew
    Hassler, Carla
    Runyon, Scott
    Pravetoni, Marco
    [J]. MOLECULAR PHARMACEUTICS, 2018, 15 (11) : 4947 - 4962
  • [10] Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex
    Beck, Zoltan
    Torres, Oscar B.
    Matyas, Gary R.
    Lanar, David E.
    Alving, Carl R.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2018, 275 : 12 - 19